| Melissa Foster, DPM | |
|
736 Cambridge St, Brighton, MA 02135-2907 | |
| (847) 528-0608 | |
| Not Available |
| Full Name | Melissa Foster |
|---|---|
| Gender | Female |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 736 Cambridge St, Brighton, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942826086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 1521 (Massachusetts) | Primary |
| Provider Name | Foot And Ankle Physicians Of Ohio Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922526698 PECOS PAC ID: 5395002844 Enrollment ID: O20171208000320 |
News Archive
With many young school athletes working hard this month to prepare for fall sports, Safe Kids USA is hosting Youth Sports Safety Clinics across the country to educate parents and coaches on how to keep children safe and prevent sports injuries, including heat-related illnesses. Nearly 3/4 of U.S. households have at least one child who plays organized sports.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
REGENT is a multicenter, randomized trial for comparison of intracoronary infusion of bone marrow-derived unselected mononuclear cells (MNC) and selected CD34+CXCR4+ cells in 200 patients with acute myocardial infarction and reduced LVEF ¡Ü 40%.
Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech's patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.
Nearly two-thirds of American parents of children under 18 (65%) report at least one economic, environmental, or lifestyle factor that limits their family's ability to live a healthy life, according to a new nationwide survey conducted by The Harris Poll on behalf of Nemours Children's Health System.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Foster, DPM 736 Cambridge St, Brighton, MA 02135-2907 Ph: (617) 779-6500 | Melissa Foster, DPM 736 Cambridge St, Brighton, MA 02135-2907 Ph: (847) 528-0608 |
News Archive
With many young school athletes working hard this month to prepare for fall sports, Safe Kids USA is hosting Youth Sports Safety Clinics across the country to educate parents and coaches on how to keep children safe and prevent sports injuries, including heat-related illnesses. Nearly 3/4 of U.S. households have at least one child who plays organized sports.
Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.
REGENT is a multicenter, randomized trial for comparison of intracoronary infusion of bone marrow-derived unselected mononuclear cells (MNC) and selected CD34+CXCR4+ cells in 200 patients with acute myocardial infarction and reduced LVEF ¡Ü 40%.
Neurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of its lead product, NT-501. NT-501 uses Neurotech's patented Encapsulated Cell Technology (ECT) as a device to deliver ciliary neurotrophic factor (CNTF) to eyes of visually impaired patients with retinitis pigmentosa (RP). Neurotech is a biotechnology company specializing in the development of novel therapeutics to treat diseases of the eye. The company is headquartered in Paris.
Nearly two-thirds of American parents of children under 18 (65%) report at least one economic, environmental, or lifestyle factor that limits their family's ability to live a healthy life, according to a new nationwide survey conducted by The Harris Poll on behalf of Nemours Children's Health System.
› Verified 6 days ago
Dr. Scott M Horwitz, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 280 Washington St, Suite304a, Brighton, MA 02135 Phone: 617-254-1344 Fax: 617-783-4803 | |
Samantha Zdanowicz, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 413-512-0913 | |
Dr. Jordan Deliman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 617-779-6512 Fax: 617-779-6468 | |
Melissa Fitzgerald, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 860-877-7754 | |
Alexandra Judith Brown, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 736 Cambridge St, Brighton, MA 02135 Phone: 617-779-6500 | |
Dr. Jeffrey Michael Kittay, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 280 Washington St, Suite 202, Brighton, MA 02135 Phone: 617-254-2345 Fax: 617-254-2288 | |
Dr. David A Sipala, DPM Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 11 Nevins St Ste 501, Brighton, MA 02135 Phone: 617-779-6512 Fax: 617-779-6762 |